ASSESSMENT OF INNOVATION PROCESSES ON THE MARKET OF MEDICATIONS AS SUPPOSITORIES

Download full text PDF
DOI: https://doi.org/None
Issue: 
3
Year: 
2016

Professor E.O. Trofimova, PhD; T.Yu. Delvig-Kamenskaya, PhD; A.S. Dzyuba Saint Petersburg State Chemopharmaceutical Academy; 14A, Prof. Popov St., Saint Petersburg 197376

The carried out analysis of the innovation development of the market of suppositories is based on the classification of pharmaceutical product innovations by the level of innovativeness. The highest innovation activity on the Russian market of suppositories was achieved in the 1990s. Later on, the level of innovations introduced to the market has decreased (modified innovations have become predominant), which is one of the signs of maturity of this market. The largest number of innovations has been put into segments of anti-infective, antihemorrhoidal, and analgesic drugs. Russian manufacturers have demonstrated the important role in the innovation development of the suppository market. Their activity is associated with the formation of a diversity of novel pharmacotherapeutic segments of the suppository market, including agents having immunotropic activity and those for the treatment of dysbacteriosis or prostate diseases.
Keywords: 
pharmaceutical market
suppositories
innovation development of the market
basic
modified
incremental innovations
level of innovativeness
References: 
  1. Dzyuba A.S. Rossiyskiy rynok suppozitoriev: ocenka osnovnyh tendenciy. Remedium, 2013; 9: 44–48.
  2. Trofimova E.O., Del`vig T.Yu. Osnovy klassifikacii innovaciy v sfere sozdaniya lekarstvennyh sredstv. Novaya apteka, 2009; 1: 43–48.
  3. Krylova I. Preparat pentasa v lechenii nespecificheskogo yazvennogo kolita i bolezni Krona. Vrach, 2014;1:35–36.
  4. Potupchik T., Veselova O., E`vert L. Nurofen v rektal`nyh suppozitoriyah pri lihoradke u detey. Vrach, 2015; 1: 29–32.
  5. Mironov P.I. E`ticheskaya e`kspertiza klinicheskih issledovaniy. Hel`sinskaya deklaraciya 2008.Medicinskiy vestnik Bashkortostana, 2009; 6 (4): 82–86.
  6. Archer D.F., Fahy G.E., Viniegra-Sibal A. et al. Initial and steady – state pharmacokinetics of avaginally administered formulation of progesterone. American journal of obstetrics and gynecology, August 1995; 173 (2): 471–477.
  7. Klinicheskie rekomendacii po diagnostike i lecheniyu vzroslyh pacientov s ostrym i hronicheskim gemorroem. M., 2013;18.